Cargando…
COVID-19 infection: the China and Italy perspectives
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the COVID-19 pandemic. Since its first report in December 2019, despite great efforts made in almost every country worldwide, this disease continues to spread globally, especially in most parts of Europe, Iran, and t...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7278221/ https://www.ncbi.nlm.nih.gov/pubmed/32513951 http://dx.doi.org/10.1038/s41419-020-2603-0 |
_version_ | 1783543290150256640 |
---|---|
author | Chen, Jun Lu, Hongzhou Melino, Gerry Boccia, Stefania Piacentini, Mauro Ricciardi, Walter Wang, Ying Shi, Yufang Zhu, Tongyu |
author_facet | Chen, Jun Lu, Hongzhou Melino, Gerry Boccia, Stefania Piacentini, Mauro Ricciardi, Walter Wang, Ying Shi, Yufang Zhu, Tongyu |
author_sort | Chen, Jun |
collection | PubMed |
description | The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the COVID-19 pandemic. Since its first report in December 2019, despite great efforts made in almost every country worldwide, this disease continues to spread globally, especially in most parts of Europe, Iran, and the United States. Here, we update the recent understanding in clinical characteristics, diagnosis strategies, as well as clinical management of COVID-19 in China as compared to Italy, with the purpose to integrate the China experience with the global efforts to outline references for prevention, basic research, treatment as well as final control of the disease. Being the first two countries we feel appropriate to evaluate the evolution of the disease as well as the early result of the treatment, in order to offer a different baseline to other countries. It is also interesting to compare two countries, with a very significant difference in population, where the morbidity and mortality has been so different, and unrelated to the size of the country. |
format | Online Article Text |
id | pubmed-7278221 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-72782212020-06-09 COVID-19 infection: the China and Italy perspectives Chen, Jun Lu, Hongzhou Melino, Gerry Boccia, Stefania Piacentini, Mauro Ricciardi, Walter Wang, Ying Shi, Yufang Zhu, Tongyu Cell Death Dis Review Article The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the COVID-19 pandemic. Since its first report in December 2019, despite great efforts made in almost every country worldwide, this disease continues to spread globally, especially in most parts of Europe, Iran, and the United States. Here, we update the recent understanding in clinical characteristics, diagnosis strategies, as well as clinical management of COVID-19 in China as compared to Italy, with the purpose to integrate the China experience with the global efforts to outline references for prevention, basic research, treatment as well as final control of the disease. Being the first two countries we feel appropriate to evaluate the evolution of the disease as well as the early result of the treatment, in order to offer a different baseline to other countries. It is also interesting to compare two countries, with a very significant difference in population, where the morbidity and mortality has been so different, and unrelated to the size of the country. Nature Publishing Group UK 2020-06-08 /pmc/articles/PMC7278221/ /pubmed/32513951 http://dx.doi.org/10.1038/s41419-020-2603-0 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Review Article Chen, Jun Lu, Hongzhou Melino, Gerry Boccia, Stefania Piacentini, Mauro Ricciardi, Walter Wang, Ying Shi, Yufang Zhu, Tongyu COVID-19 infection: the China and Italy perspectives |
title | COVID-19 infection: the China and Italy perspectives |
title_full | COVID-19 infection: the China and Italy perspectives |
title_fullStr | COVID-19 infection: the China and Italy perspectives |
title_full_unstemmed | COVID-19 infection: the China and Italy perspectives |
title_short | COVID-19 infection: the China and Italy perspectives |
title_sort | covid-19 infection: the china and italy perspectives |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7278221/ https://www.ncbi.nlm.nih.gov/pubmed/32513951 http://dx.doi.org/10.1038/s41419-020-2603-0 |
work_keys_str_mv | AT chenjun covid19infectionthechinaanditalyperspectives AT luhongzhou covid19infectionthechinaanditalyperspectives AT melinogerry covid19infectionthechinaanditalyperspectives AT bocciastefania covid19infectionthechinaanditalyperspectives AT piacentinimauro covid19infectionthechinaanditalyperspectives AT ricciardiwalter covid19infectionthechinaanditalyperspectives AT wangying covid19infectionthechinaanditalyperspectives AT shiyufang covid19infectionthechinaanditalyperspectives AT zhutongyu covid19infectionthechinaanditalyperspectives |